Other upcoming conferences produced by EOCI include:

Congress Learning Objectives

Following this program, participants will be able to:

  • Evaluate, recognize and treat patients with advanced heart failure
  • Approach the increasing problem of right sided heart failure
  • Identify novel structural heart and surgical interventions
  • Identify how recent advances in genetics, stem cell and regenerative medicine will impact your patients with heart failure
  • Treat complex heart failure cases including those with multiple comorbid conditions

Joint Plenary Session: Advanced Heart Failure Part I: Early Recognition, Prevention & Referral

What is advanced HF and why is it on the rise?

At the end of the session, participants will be able to:

  1. Recognize advanced heart failure in its early stages to facilitate optimal intervention.
  2. Categorize the varying levels of severity that may present in advanced heart failure.
  3. Effectively refer patients with advanced heart failure for individually appropriate treatment and follow-up.

The latest on acute hear failure

At the end of the session, participants will be able to:

  1. Risk stratify patients upon diagnosis of acute heart failure.
  2. Triage acute heart failure patients for follow-up at discharge hospital, utilizing the latest assessments and most reliable biomarkers.
  3. Describe novel acute failure therapies under investigation.

How can we help people with diabetes prevent chronic and acute heart failure?

At the end of the session, participants will be able to:

  1. Recognize that heart failure is the major cardiovascular sequelae of type 2 diabetes.
  2. Recognize that coexistence of DM and HF is associated with poor outcomes
  3. Identify therapies of DM which affect HF outcomes

Down the rabbit hole of mechanical circulatory support

At the end of the session, participants will be able to:

  1. Select appropriate treatment strategies for rapidly progressive heart failure.
  2. Develop strategies for indolent advanced heart failure.
  3. Effectively employ the use of temporary mechanical support or the use of durable support in patients with advanced heart failure.

Recovery – from the myocardium to patient quality of life

At the end of the session, participants will be able to:

  1. Describe myocardial recovery.
  2. Estimate those patients with advanced heart failure who are most likely to experience myocardial recovery.
  3. Recognize the proposed mechanisms of myocardial recovery and how reliable its durability is in most patients.
  4. Identify utility of patient reported outcomes in treatment decisions in advanced heart failure.

Heart failure and atrial fibrillation: chicken or the egg?

At the end of the session, participants will be able to:

  1. Define the features common to both atrial fibrillation and heart failure.
  2. Assess how beta blockade may affect heart failure differently in the setting of concurrent atrial fibrillation.
  3. Contrast cases where heart failure is a complication of atrial fibrillation, as opposed to atrial fibrillation a complication of heart failure.

Plenary Session: The Many Considerations of Complex HF Care

Practical integration of genetics in HF management

At the end of the session, participants will be able to:

  1. Review the genetic bases of heart failure.
  2. Evaluate available clinical grade genetics tests currently recommended for the diagnosis and management of heart failure.
  3. Describe how rapidly evolving technology – such as whole genome and whole exome sequencing – is changing the genetic landscape of heart failure in terms of research and patient care.
  4. Interpret how genetic information may guide heart failure therapy.

HFpEF: Mythbuster

  1. Discuss the common misconceptions surrounding HFpEF.
  2. Identify patients presenting with mid-range ejection fraction.
  3. Assess the ideal strategies for directing therapy for HFpEF patients.

Managing HF patients with renal disease and anemia

At the end of the session, participants will be able to:

  1. Describe how to effectively recognize and treat cardiorenal syndrome. 
  2. Estimate in which cases and at what point to deliver intravenous I.V. iron therapy and new data on oral iron therapy.
  3. Discuss the role of renal replacement therapy in the treatment of heart failure.

Clips, sparks and implantable monitors for heart failure

At the end of the session, participants will be able to:

  1. Identify those patients to consider referring for percutaneous mitral valve therapy.
  2. Distinguish patients with heart failure reduced ejection fraction for treatment with ID, CRT, both or neither.
  3. Identify potential patients who would benefit from implantable hemodynamic monitoring.

Plenary Session: Right Heart Failure

Evaluation and Management of Right Heart Failure

At the end of the session, participants will be able to:

  1. Describe the presentations of right-sided heart failure
  2. Detect isolated right-sided heart failure.
  3. Estimate when a right heart catheterization is appropriate for heart failure patients.

Imaging of the right ventricle

At the end of the session, participants will be able to:

  1.  Describe the advantages and pitfalls of non-invasive imaging for the diagnosis of pulmonary arterial hypertension.
  2.  Understand currently available tools for assessing right ventricular function.
  3.  Identify emerging non-invasive techniques to assess right ventricular and atrial disease.

When should you operate on the right ventricle?

At the end of the session, participants will be able to:

  1. Review emerging indications for tricuspid valve interventions in patients with right heart failure.
  2. Order timely patient referrals for right ventricular intervention.
  3. Effectively manage heart failure patients in preparation for right ventricular intervention.

Clinical Workshops

Management of HFpEF

At the end of this interactive workshop, participants will be able to:

  1. Identify the latest techniques in the diagnosis of HFpEF.
  2. Define the treatments used for patients with HFpEF.
  3. Compare current studies underway or recently completed on optimal management of patients with HFpEF.

CCS Heart Failure Guidelines ReLoad

At the end of this interactive workshop participants will be able to:

  1. Identify a clear approach to diagnosis and management of each patient with heart failure (through case-based discussions).
  2. Optimize pharmacotherapy considering new data and newly available therapies.
  3. Review advanced therapies and discuss the essentials of what you need to know.

The who, what and how of advocacy for HF survivors

At the end of this interactive workshop, participants will be able to:

  1. Advocate for better resources to improve the quality of life for patients with heart failure;
  2. Identify tools patients can use to interact with others diagnosed with heart failure;
  3. Provide patients with tools they can use to self-manage heart failure.

Goals of care and advanced HF symptom management

At the end of this interactive workshop, participants will be able to:

  1. Provide supportive treatment for patients with advanced heart failure symptoms that are refractory to standard therapy. 
  2. Review goals of care with patients and informal caregivers through an empathetic and effective discourse.
  3. Avoid patient hospitalization and ER visits when nearing end of life.

E-health: taking advantage of technology

At the end of this interactive, case-based workshop, participants will be able to:

  1. Apply e-health approaches that facilitate efficient, timely interaction with heart failure patients.
  2. Recognize when and how a phone call is best used in patient management.
  3. Describe how added e-health technology in the home can optimize patient monitoring.
  4. Determine the situations where more complex e-health platforms are indicated.

How to use biomarkers for your heart failure patients

At the end of this interactive workshop, participants will be able to:

  1. Leverage heart failure biomarkers to improve patient care and management.
  2. Relate emerging uses of biomarkers for the prevention of heart failure hospitalization.
  3. Identify novel heart failure-related biomarkers currently under investigation.

Is this recovered heart failure?

At the end of this interactive workshop, participants will be able to:

  1. Describe heart failure recovery.
  2. Identify settings where heart failure therapies may be withdrawn.
  3. Develop a working approach to how one determines if a patient has heart failure recovery.

Unusual and interesting heart failure cases

At the end of this interactive workshop, participants will be able to:

  1. Employ a critical thinking approach for managing complex patients who are being considered for MCS/transplant.
  2. Develop strategies to explore and manage patients who have difficulty with self-care.
  3. Understand the importance of prognosis assessment and expected disease course as a key factor for timing medical decisions.

Expanding knowledge and awareness in time for the coming HF tsunami

At the end of this interactive workshop, participants will be able to:

  1. Recognize the needs of an increasingly prevalent heart failure patient population.
  2. Employ strategies that enhance heart failure care capacity on the community level.
  3. Describe the requirements for competency in heart failure patient care.

Ted Rogers Centre Scientific Sessions

Targeting Regenerative Medicine

Injectable biomaterials for treating myocardial infarction and heart failure

At the end of this interactive session, participants will be able to:

  1. Review the current state of cardiac-related biomaterials, and what advances are on the forefront.
  2. Discuss translational challenges for injectable biomaterials for treating heart failure.

Cardiac patterning in zebrafish: Signaling pathways that establish and reinforce cardiac cell fates

At the end of this interactive session, participants will be able to:

  1. Describe our current understanding of the genetic pathways that assign cardiac cell fates.
  2. Relate the mechanisms that specify cardiac cell identity to potential future applications in regenerative medicine.

Translating human development to new therapies with pluripotent stem cells

At the end of this interactive session, participants will be able to:

  1. Discuss human pluripotent stem cells (hPSCs) and their clinical applications.
  2. Relay strategies for the directed differentiation of hPSCs to functional cell types.
  3. Discuss the generation of human cardiac cells for the treatment of cardiovascular disease.

Targeting Inflammation

Targeting inflammation in Secondary Prevention: What will CIRT and CANTOS tell us?

At the end of this interactive session, participants will be able to:

  1. Trace the basic and translational biology of inflammation as it relates to the pathobiology of cardiometabolic diseases.
  2. Review the role of pharmacological targeting with specific (anti-IL1-β antibodies) and non-specific (methotrexate, colchicine) on secondary prevention outcomes.
  3. Discuss the safety of inflammation reduction approaches in secondary prevention of heart failure.

The original biologic cardiovascular therapy? Influenza vaccination for secondary prevention

At the end of this interactive session, participants will be able to:

  1. Review the burden of cardiovascular complications associated with influenza.
  2. Examine the data in support of influenza infection as a systemic, inflammatory disease.
  3. Evaluate the effectiveness of influenza vaccination in the prevention of influenza and subsequent cardiovascular complications.
  4. Discuss the rationale and design of a new RCT comparing two influenza vaccine strategies for secondary prevention in patients with MI or HF.

Resveratrol in heart failure: an anti-inflammatory effect?

At the end of this interactive session, participants will be able to:

  1. Understand the pathogenesis of heart failure in a variety of settings.
  2. Understand the CV benefits of resveratrol.
  3. Discuss the therapeutic potential of resveratrol in heart failure.
  4. Discuss the concept that heart failure may be a metabolic disease.

Innovation Awards

Analysis of novel regulators of cardiac function in cardiomyocytes and zebrafish models

At the end of this interactive session, participants will be able to:

  1. Relate what unbiased proteomic analyses can provide in the setting of heart failure.
  2. Assess how candidate proteins that are found to be disturbed in heart failure can help direct mechanistic studies of the disease.
  3. Identify which model systems can be used most effectively to study candidate protein perturbations.

Development of a novel device for treatment of failing Fontan circulation

  1. Describe Fontan circulation and the additional challenge it poses to the treatment of patients with congenital heart disease.
  2. Review the current therapies available for treating failing Fontan circulation, as well as what new approaches are on the horizon.
  3. Assess which areas of investigation are required to expand the therapeutic base for this condition.

Multifactorial immune cell based development of non-ischemic cardiomyopathy

  1. Review the immune system residing in the myocardium.
  2. Describe how the immune system interacts with and impacts heart failure.
  3. Discuss the potential impact of viral myocarditis and associated immune-responses in hypertension-driven heart failure.

Targeting Fibrosis

Therapeutic targeting of organ fibrosis

At the end of this interactive session, participants will be able to:

  1. Interpret the role of fibroblasts in the pathogenesis of tissue fibrosis and organ failure.
  2.  Explore new molecular pathways as therapeutic targets in organ fibrosis.

Novel approaches to target myocardial inflammation & fibrosis

At the end of this interactive session, participants will be able to:

  1. Describe the mechanisms of myocarditis and the related inflammatory process of myocardial fibrosis.
  2. Distinguish the role of the chemokine network in driving cardiac inflammation.
  3. Summarize novel anti-inflammatory and anti-fibrotic therapeutics.

Cardiac fibrosis: Letting the "KAT" out of the HAT is “SirT1”ainly NOT a good idea

At the end of this interactive session, participants will be able to:

  1. Describe the burden of fibrotic conditions leading to impaired organ function
  2. Discuss the acetylome and its impact on non-histone protein function
  3. Review new antifibrotic strategies focusing on Smad acetylation/deacetylation

Debates

Be it resolved that all patients with heart failure and atrial fibrillation should be cardioverted at least once.

At the end of this debate (featuring audience interaction), participants will be able to:

  1. Detail how prevalent atrial fibrillation is in heart failure, and in which patients it tends most to occur.
  2. Trace the impacts of atrial fibrillation on quality of life, symptoms, exercise capacity and prognosis as it relates to heart failure.
  3. Effectively select patients with atrial fibrillation for elective cardioversion, and estimate its success rate in those patients who also have heart failure.
  4. Describe the durability of sinus rhythm following cardioversion with or without adjunctive medical therapy.

CPAP to treat obstructive sleep apnea provides cardiovascular benefit.

At the end of this debate (featuring audience interaction), participants will be able to:

  1. Estimate how common sleep apnea is in patients with heart failure.
  2. Recognize various grades of sleep apnea that require CPAP treatment.
  3. Specify the benefits of CPAP in general as well as specifically in context of heart failure.
  4. Recite findings from key clinical trials regarding the pathogenesis and treatment of cardiovascular disease, and specifically heart failure.